12/10/2025
Bundle up and breathe easy! 💨 Here’s how to keep COPD symptoms in check this winter.
Check you the full article here:
https://bit.ly/4afgCid 🧣
Pulmonx has developed the Zephyr® Endobronchial Valve Therapy, a minimally invasive treatment for severe COPD/emphysema.
700 Chesapeake Drive
Redwood City, CA
94063
| Monday | 9am - 5pm |
| Tuesday | 9am - 5pm |
| Wednesday | 9am - 5pm |
| Thursday | 9am - 5pm |
| Friday | 9am - 5pm |
Be the first to know and let us send you an email when Pulmonx posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Send a message to Pulmonx:
Pulmonx has developed the Zephyr Endobronchial Valve Therapy, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done during a simple bronchoscopy that require no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation and preventing air from getting trapped in the diseased parts of the lung allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1 Patients treated report immediate relief and the ability to go back to doing everyday tasks with ease.
The Zephyr Valves were approved by the FDA in June 2018. Since 2007, more than 15,000 patients have been treated with the Zephyr Valve worldwide. The Zephyr Valve is included in emphysema treatment guidelines issued by leading health organizations worldwide, including the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the UK’s National Institute for Health and Care Excellence (NICE).
Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.1
1. Criner G et al AM J Resp Crit Care Med 2018, Published on 22-May-2018 as 10.1164/rccm.201803-0590OC